The estimated Net Worth of Phillip G. Febbo is at least $2.59 million dollars as of 21 February 2023. Phillip Febbo owns over 3,522 units of Varian Medical Systems stock worth over $140,134 and over the last 9 years he sold VAR stock worth over $2,429,824. In addition, he makes $25,000 as Independent Director at Varian Medical Systems.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Phillip Febbo VAR stock SEC Form 4 insiders trading
Phillip has made over 16 trades of the Varian Medical Systems stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 3,522 units of VAR stock worth $58,236 on 21 February 2023.
The largest trade he's ever made was selling 6,324 units of Varian Medical Systems stock on 10 May 2016 worth over $172,013. On average, Phillip trades about 1,117 units every 73 days since 2015. As of 21 February 2023 he still owns at least 8,475 units of Varian Medical Systems stock.
You can see the complete history of Phillip Febbo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Phillip Febbo biography
Dr. Phillip G. Febbo M.D. serves as Independent Director of the Company. ?Chief Medical Officer, Illumina, Inc. (March 2018—present) • ?Chief Medical Officer, Genomic Health, Inc. (2013—March 2018) • ?Professor of Medicine and Urology at the University of California, San Francisco (UCSF) (2010—2013) • ?Service on the board of directors of the American College of Medical Genetics and Genomics Foundation (2018—present).
What is the salary of Phillip Febbo?
As the Independent Director of Varian Medical Systems, the total compensation of Phillip Febbo at Varian Medical Systems is $25,000. There are 10 executives at Varian Medical Systems getting paid more, with Dow Wilson having the highest compensation of $9,446,300.
How old is Phillip Febbo?
Phillip Febbo is 54, he's been the Independent Director of Varian Medical Systems since 2019. There are 9 older and 4 younger executives at Varian Medical Systems. The oldest executive at Varian Medical Systems, Inc. is David Illingworth, 66, who is the Independent Director.
What's Phillip Febbo's mailing address?
Phillip's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, , SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Varian Medical Systems
Over the last 22 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin et Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.
What does Varian Medical Systems's logo look like?
Complete history of Phillip Febbo stock trades at Illumina Inc, Veracyte Inc et Varian Medical Systems
Varian Medical Systems executives and stock owners
Varian Medical Systems executives and other stock owners filed with the SEC include:
-
Dow Wilson,
Chief Executive Officer, Director -
Kolleen Kennedy,
President - Proton Solutions Division and Chief Growth Officer -
Chris Toth,
President, Chief Operating Officer -
R. Andrew Eckert,
Independent Chairman of the Board -
Jeffrey Balser,
Independent Director -
Judy Bruner,
Independent Director -
Anat Ashkenazi,
Independent Director -
Jean-Luc Butel,
Independent Director -
Regina Dugan,
Independent Director -
David Illingworth,
Independent Director -
Phillip Febbo,
Independent Director -
Michael Hutchinson,
Senior Vice President, Chief Legal Officer -
Francis Facchini,
President, Interventional Solutions Business -
Anshul Maheshwari,
Vice President, Treasurer and Investor Relations -
Michelle Le Beau,
Independent Director -
J. Michael Bruff,
Chief Financial Officer, Senior Vice President - Finance -
Magnus Momsen,
SVP, CAO, Corporate Controller -
Mark R Laret,
Director -
Jose Baselga,
Director -
John W Kuo,
SVP, Gen Counsel and Secretary -
Gary E Jr Bischoping,
SVP, Finance & CFO -
Susan L Bostrom,
Director -
Timothy E Guertin,
Director -
Clarence R Verhoef,
SVP, Finance, Corp Controller -
Venkatraman Thyagarajan,
Director -
Sunny Sanyal,
SVP and President, ICB -
Robert H Kluge,
Corporate Vice President -
Richard M Levy,
President and CEO -
Ruediger Naumann Etienne,
Director -
John Seely Brown,
Director -
Erich R Reinhardt,
Director -
Tai Yun Chen,
VP and Corporate Controller -
David W Jr Martin,
Director -
Steven A Leibel,
Director -
Kent J Thiry,
Director -
Allen S Lichter,
Director -
Samuel Hellman,
Director -
Crisanto C Raimundo,
Corporate Controller -
Terry R Lautenbach,
Director -
Joseph B Phair,
VP Admin,Gen Counsel,Secretary -
Elisha W Finney,
Corporate Vice President & CFO -
Kevin O'reilly,
SVP, President of Oncology Sys